HomePLX • NYSEAMERICAN
add
Protalix Biotherapeutics Inc
Previous close
$2.26
Day range
$2.17 - $2.28
Year range
$0.82 - $2.36
Market cap
167.15M USD
Avg Volume
486.07K
P/E ratio
-
Dividend yield
-
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 17.96M | 73.60% |
Operating expense | 5.59M | -23.79% |
Net income | 3.24M | 274.73% |
Net profit margin | 18.02 | 200.67% |
Earnings per share | — | — |
EBITDA | 4.32M | 373.07% |
Effective tax rate | 15.79% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 27.41M | -33.11% |
Total assets | 61.56M | -29.70% |
Total liabilities | 29.13M | -40.95% |
Total equity | 32.44M | — |
Shares outstanding | 73.63M | — |
Price to book | 5.14 | — |
Return on assets | 13.03% | — |
Return on capital | 21.49% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | 3.24M | 274.73% |
Cash from operations | 4.10M | 159.60% |
Cash from investing | 20.33M | 197.36% |
Cash from financing | -20.42M | — |
Net change in cash | 4.01M | 114.44% |
Free cash flow | 1.05M | 113.52% |
About
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease. Wikipedia
CEO
Founded
1993
Headquarters
Website
Employees
208
